The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLV.f

Pneumothorax

Rapid shrinkage of neoplastic pulmonary lesions denothic therapeutic efficacy may lead to cavitation, pneumothorax and hemoptysis

Publications

Sakhri L, Meynet E, Ferrer L, Pirvu A, Ferretti G, Moro-Sibilot D

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report.

Journal of medical case reports 2014 Oct 09;8;335 — 2014 Oct 09 — 335

Gennatas S, Stanway SJ, Thomas R, Min T, Shah R, O'Brien ME, Popat S

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma.

BMC cancer 2013 Apr 26;13;207 — 2013 Apr 26 — 207